ArticleBlood red cells & iron2025
Longitudinal changes and predictors of cardiac extracellular volume fraction in sickle cell anemia.
Article in Blood red cells & iron, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02410811 (Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diffuse myocardial fibrosis is a key feature of the cardiomyopathy of sickle cell anemia (SCA) that is linked to diastolic dysfunction. Cardiac MRI (CMR)-derived extracellular volume fraction (ECV) is a quantitative biomarker of myocardial fibrosis that is elevated in SCA. The stability of ECV in SCA and its clinical associations over time are unknown. To measure longitudinal changes in ECV, without specific intervention, and identify correlates of ECV change in patients with SCA, we conducted a prospective, 2-year study involving annual CMR, echocardiography, and laboratory assessments in 24 patients with SCA (mean age 21.4±10 years). ECV was calculated using T1 mapping pre- and post-gadolinium, and extracellular matrix and cellular volumes were calculated to account for relative changes. Diastolic function was classified by echocardiography. Longitudinal associations were assessed using linear mixed-effects models. ECV was abnormally increased at baseline and remained stable over time (mean change -1.1±2.7% per year). Intra-subject ECV variability was low (mean 2.4%), with no differences by age or sex. ECV correlated with diastolic dysfunction at all timepoints (P=0.01). Changes in ECV were more closely associated with changes in extracellular matrix volume (P=0.01) than with myocardial cell volume. In a longitudinal multivariable analysis, ECV was independently associated with diastolic dysfunction, hemoglobin, NT-proBNP, left atrial volume, and peak pulmonary artery velocity. In summary, ECV is a stable and reliable metric of myocardial extracellular matrix expansion in SCA. Its strong associations with diastolic dysfunction and biomarkers of cardiac stress support its use as an imaging biomarker for antifibrotic therapies in SCA. This trial was registered at www.ClinicalTrials.gov as #NCT02410811.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.